Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Findings could lead to treatments for blood disorders associated with iron deficiencies and overloads

Findings could lead to treatments for blood disorders associated with iron deficiencies and overloads

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

Scientists find interplay between two specific proteins crucial for flawless repair of crosslink damage

Scientists find interplay between two specific proteins crucial for flawless repair of crosslink damage

Scientists develop 3-D artificial enzyme cascade that mimics biochemical pathway using DNA molecules

Scientists develop 3-D artificial enzyme cascade that mimics biochemical pathway using DNA molecules

Immucor's PreciseType HEA test receives FDA approval to predict blood compatibility

Immucor's PreciseType HEA test receives FDA approval to predict blood compatibility

New project aims at saving lives of mothers, newborns in developing countries

New project aims at saving lives of mothers, newborns in developing countries

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Psychologists and physicians help address barriers to improved primary health care

Psychologists and physicians help address barriers to improved primary health care

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva's SYNRIBO for injection receives FDA approval for home administration

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.